Company Overview

Exagen Inc. is a U.S.-based diagnostics company focused on autoimmune disease testing, with a primary emphasis on rheumatology and related chronic autoimmune conditions. The company develops, commercializes, and operates laboratory testing services intended to support earlier and more accurate diagnosis, prognosis, and disease management for conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and other connective tissue diseases. Exagen operates within the molecular diagnostics, clinical laboratory services, and precision medicine industries, with revenue primarily generated through reimbursement for proprietary diagnostic testing services provided to physicians, healthcare systems, and payors.

The company’s principal commercial offering is the AVISE® testing portfolio, including AVISE® CTD, which combines biomarker analysis, cell-bound complement activation products, and algorithmic interpretation intended to improve autoimmune disease differentiation. Exagen was founded in 2002 and evolved from a specialty diagnostics enterprise into a focused autoimmune testing company through internal assay development, clinical validation programs, and commercialization efforts targeting rheumatologists across the United States. Its strategic positioning is tied to proprietary biomarker technology, established rheumatology relationships, and a concentrated focus on autoimmune diagnostics rather than broader general laboratory services.

Business Operations

Exagen primarily operates through a single-reportable diagnostics business centered on its AVISE® product portfolio and associated laboratory services. The company generates revenue by performing diagnostic tests at its CLIA-certified and CAP-accredited laboratory operations in the United States, with reimbursement derived from commercial insurers, government healthcare programs, healthcare institutions, and direct billing arrangements. The company’s testing menu includes products focused on lupus assessment, connective tissue disease differentiation, rheumatoid arthritis, and related autoimmune conditions. Exagen’s operations are largely domestic, though its technologies and intellectual property have relevance to broader global autoimmune diagnostics markets.

The company controls proprietary biomarker technologies, diagnostic algorithms, laboratory processes, and clinical datasets supporting its testing platform. Exagen has invested in physician education, clinical utility studies, and reimbursement expansion to support commercial adoption. Public filings and company disclosures indicate relationships with healthcare providers, payors, and laboratory partners supporting commercialization and distribution activities. Data regarding material international joint ventures or large-scale foreign operating subsidiaries is inconclusive based on available public sources.

Strategic Position & Investments

Exagen’s strategic direction has centered on expanding adoption of its autoimmune diagnostic portfolio, increasing test utilization among rheumatologists, strengthening reimbursement coverage, and generating additional clinical evidence supporting the utility of its proprietary assays. The company has invested in research and development tied to biomarker discovery, machine-learning-supported diagnostics, and expanded autoimmune disease applications. Management has also emphasized operational efficiency, sales force productivity, and broader physician penetration as key growth initiatives in recent corporate communications and SEC disclosures.

The company’s investment priorities have included laboratory infrastructure, assay enhancement, intellectual property protection, and clinical validation studies supporting payer acceptance and physician adoption. Exagen has continued developing additions to the AVISE® platform and associated testing capabilities rather than pursuing large-scale diversification outside autoimmune diagnostics. Publicly available information does not indicate major transformative acquisitions comparable to larger diagnostics industry consolidators. The company remains primarily focused on specialty autoimmune testing and precision diagnostics within rheumatology care.

Geographic Footprint

Exagen is headquartered in Carlsbad, California, and primarily serves the United States healthcare market. Its commercial infrastructure is focused on U.S. rheumatologists, specialty clinics, hospitals, and healthcare networks. The company’s laboratory operations and reimbursement framework are heavily aligned with the U.S. healthcare and insurance environment, including relationships with commercial and government payors.

While Exagen’s operational footprint is predominantly domestic, its diagnostic technologies and intellectual property contribute to broader participation in the global autoimmune diagnostics sector. Available public disclosures indicate that the company’s direct revenue exposure outside the United States remains limited relative to larger multinational diagnostics companies. Data regarding material international operational hubs or extensive foreign investment activities is inconclusive based on available public sources.

Leadership & Governance

Exagen’s leadership team oversees a strategy focused on autoimmune diagnostics expansion, clinical evidence generation, reimbursement optimization, and physician adoption within rheumatology markets. The company was founded by entrepreneurs and healthcare industry professionals seeking to improve autoimmune disease detection through specialized biomarker-based diagnostics. Corporate governance is overseen by a board of directors and executive management team responsible for operational execution, regulatory compliance, commercialization strategy, and capital allocation as reflected in public company filings.

Key executives and leadership figures include:

• John Aballi – President and Chief Executive Officer
• Brent Jones – Chief Financial Officer
• John Niland – Chief Operating Officer
• Lauren Kraus – Chief Commercial Officer

Management communications and SEC disclosures indicate that leadership strategy has emphasized disciplined commercial expansion, evidence-based diagnostics, payer engagement, and the integration of precision medicine approaches into rheumatology care pathways.